Clinical Trial Detail

NCT ID NCT02109744
Title Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Rochester
Indications

acute myeloid leukemia

Therapies

Decitabine + Sirolimus

Decitabine + Ribavirin

Age Groups: senior adult

No variant requirements are available.